Phase 1 Study Evaluating Genetically Modified Autologous T-cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients with Recurrent and/or Refractory Solid Tumors (ACTengine IMA202-101)
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / email@example.com
The goal of the overall study is to learn if it is safe to give genetically changed T cells (IMA202) in combination with standard of care chemotherapy (fludarabine and cyclophosphamide) and IL-2 (aldesleukin) to patients with melanoma solid tumors that have grown or returned after being treated. Researchers also want to learn about possible side effects of IMA202 and if the study drug can help to control the disease.
This study is closed
Ran Reshef, MD
|Are you at least 18 years of age?
|Do you have recurrent (come back) or refractory (does not respond to treatment) melanoma?
|Are you willing to undergo testing, such as biopsies and blood draws?